Search Results
Sep 18, 2025, 22:26 ET Grvt Raises $19M to Pioneer Privacy-First Onchain Finance and Unlock Trillion-Dollar Markets
product will ensure a 10% interest rate return for all users. We will also introduce our flagship market-making strategy, the Grvt Liquidity Provider (GLP), a fund strategy that provides high double-digit APRs, which was once inaccessible to retail traders. Amid the industry's rapid growth, this
More news about: GRVT
Sep 18, 2025, 22:16 ET Grvt Raises $19M to Pioneer Privacy-First Onchain Finance and Unlock Trillion-Dollar Markets
product will ensure a 10% interest rate return for all users. We will also introduce our flagship market-making strategy, the Grvt Liquidity Provider (GLP), a fund strategy that provides high double-digit APRs, which was once inaccessible to retail traders. Amid the industry's rapid growth, this
More news about: GRVT
Sep 18, 2025, 17:58 ET Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: Faruqi & Faruqi, LLP
Sep 18, 2025, 15:40 ET Orforgliprona, GLP-1 oral da Lilly, é superior à semaglutida oral em estudo head-to-head
Sobre a orforgliprona A orforgliprona é uma pequena molécula (não peptídica) agonista do receptor do peptídeo semelhante ao glucagon-1 (GLP-1) oral, experimental, de dose única diária, que pode ser tomada a qualquer hora do dia sem restrições de alimentos e água7. A orforgliprona
More news about: Eli Lilly do Brasil
Sep 18, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
attributed the reduction to "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." On this news, Novo Nordisk's American Depositary Receipt ("ADR") price fell $15.06
More news about: Pomerantz LLP
Sep 18, 2025, 09:00 ET QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025
gastrointestinal adverse events (AEs) was similar to that of marketed GLP-1 RA products. The most common treatment-related AEs were nausea, vomiting, and diarrhea, all which occurred mainly during the GLP-1 RA common dose escalation period. Thereafter, these AEs decreased after
More news about: QL Biopharm
Sep 18, 2025, 09:00 ET New Research Strengthens Evidence of Cranberry Health Benefits
Christensen S, Robinson K, Thomas S, Williams DR. Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obes Pillars. 2024 Jul 25;11:100121. doi: 10.1016/j.obpill.2024.100121.
More news about: The Cranberry Institute
Sep 18, 2025, 08:45 ET The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Lawsuit - NVO
impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo's branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo's capability to penetrate said markets
More news about: The Gross Law Firm
Sep 18, 2025, 08:00 ET Le-Vel Celebrates Lucky 13 Years of THRIVING: A Legacy of Innovation, Impact, and Community
Experience, the advanced THRIVE ELITE Experience, and its newest innovation, myGLP—a holistic dietary system designed to support the body's natural GLP-1 production for healthy metabolism, digestion, mental clarity, and appetite control. With more than 10 million Customer and Brand Promoter accounts,
More news about: Le-Vel Brands
Sep 17, 2025, 19:30 ET Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025
and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy
More news about: Ascletis Pharma Inc.
Sep 17, 2025, 18:57 ET NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood that such patients would switch to Novo Nordisk's branded alternatives. Further, defendants greatly overstated the potential GLP-1 market or otherwise, Novo's capability to penetrate
More news about: THE ROSEN LAW FIRM, P. A.
Sep 17, 2025, 18:01 ET EADV Congress 2025: GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients
diabetes or obesity over a two-year period, including 3,048 who were treated with GLP-1RAs and 3,048 who received other anti-diabetic or anti-obesity drugs. After matching for age, sex, and comorbidities, the benefits of GLP-1RAs were clear and consistent across all sensitivity analyses, using propensity
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 17, 2025, 18:01 ET EADV-Kongress 2025: GLP-1RA-Medikamente verringern das Sterbe- und Herz-Kreislauf-Risiko bei Psoriasis-Patienten drastisch
Zeitraum von zwei Jahren, darunter 3.048, die mit GLP-1RAs behandelt wurden, und 3.048, die andere Medikamente gegen Diabetes oder Fettleibigkeit erhielten. Nach dem Abgleich für Alter, Geschlecht und Begleiterkrankungen waren die Vorteile von GLP-1RAs in allen Sensitivitätsanalysen eindeutig und
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 17, 2025, 18:01 ET Congreso EADV 2025: Los fármacos GLP-1RA reducen el riesgo cardiovascular en pacientes con psoriasis
obesidad, durante un período de dos años, incluyendo 3.048 tratados con GLP-1RAs y 3.048 que recibieron otros fármacos antidiabéticos o antiobesidad. Tras el emparejamiento por edad, sexo y comorbilidades, los beneficios de GLP-1RAs fueron claros y consistentes en todos los análisis de sensibilidad,
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 17, 2025, 18:01 ET Congrès EADV 2025 : Les médicaments GLP-1RA réduisent considérablement la mortalité et le risque cardiovasculaire chez les patients atteints de psoriasis
sur une période de deux ans, dont 3 048 ont été traités avec des GLP-1RA et 3 048 ont reçu d'autres médicaments contre le diabète ou l'obésité. Après avoir pris en compte l'âge, le sexe et les comorbidités, les avantages des GLP-1RA étaient clairs et cohérents dans toutes les analyses de sensibilité,
More news about: European Academy of Dermatology and Venereology (EADV) Congress 2025
Sep 17, 2025, 18:01 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) dual receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the
More news about: Eli Lilly and Company
Sep 17, 2025, 16:14 ET Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize
More news about: Law Offices of Howard G. Smith
Sep 17, 2025, 13:09 ET Reported in the Journal of the American Medical Association (JAMA): Bariatric surgery offers greater weight loss, lower costs over time compared to GLP-1s, Highmark Health research demonstrates
For obese patients, bariatric surgery achieves greater weight loss at lower ongoing cost when compared to the class of medications commonly known as GLP-1s, according to a new study authored by Highmark Health researchers and published through the Journal of the American Medical Association (JAMA).
More news about: Highmark Health
Sep 17, 2025, 09:00 ET Cirius Therapeutics, Breakthrough T1D and UVA Health Collaborate on Phase 2 Study of MPC Inhibitor CIR-0602K in Type 1 Diabetes
beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue includes dramatic
More news about: Cirius Therapeutics
Sep 17, 2025, 09:00 ET Hydroxycut Expands Accessible Weight Loss and Weight Maintenance Product Line at Walmart: New Hunger Control + Weight Loss Drink Sticks
Hydroxycut's recent research shows that 44% of consumers identify as "cautiously curious" about GLP-1s, interested but not ready to commit to a prescription or injection. Even more, both current and past GLP-1 users are increasingly turning to over-the-counter options by way of weight-loss supplements
More news about: Hydroxycut
Sep 17, 2025, 09:00 ET Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024 Apr;15(4):819-832.
More news about: Eli Lilly and Company
Sep 17, 2025, 08:42 ET Supergut Debuts New Product: Foundational Daily Fiber
lineup of the GLP-1 Booster fiber blend, all developed to help you feel superhuman from the inside out. While both fiber blends are rooted in Supergut's premium ingredient approach to gut health, Foundational Daily Fiber and the GLP-1 Booster serve distinct
More news about: Supergut
Sep 17, 2025, 08:12 ET NOVO NORDISK A/S (NYSE: NVO) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by September 30, 2025
HERE. On July 29, 2025, Novo lowered its sales and profit guidance for the second half of fiscal 2025, citing persistent use of compounded GLP-1s, slower-than-expected market expansion, and increased competition for both Wegovy® and Ozempic®. In reaction, Novo's stock price plunged from $69.00 to $53.94 per
More news about: Berger Montague
Sep 16, 2025, 19:30 ET Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
"Ascletis") announces that results from cohorts 1 and 2 of 28-day multiple ascending dose (MAD) study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440)
More news about: Ascletis Pharma Inc.
Sep 16, 2025, 18:01 ET Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses
More news about: Eli Lilly and Company